Cancer Research Audrey Hepburn EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grandemange, S.
Right arrow Articles by Wrutniak-Cabello, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grandemange, S.
Right arrow Articles by Wrutniak-Cabello, C.
[Cancer Research 65, 4282-4291, May 15, 2005]
© 2005 American Association for Cancer Research

Cell and Tumor Biology

Stimulation of Mitochondrial Activity by p43 Overexpression Induces Human Dermal Fibroblast Transformation

Stéphanie Grandemange1, Pascal Seyer1, Angel Carazo1, Philippe Bécuwe3, Laurence Pessemesse1, Muriel Busson1, Cécile Marsac4, Pascal Roger2, François Casas1, Gérard Cabello1 and Chantal Wrutniak-Cabello1

1 UMR 866, Différenciation Cellulaire et Croissance (INRA-UMII-ENSAM), Unité d'Endocrinologie Cellulaire, Institut National de la Recherche Agronomique; 2 Laboratoire d'Anatomie et Cytologie Pathologiques, Hôpital Lapeyronie, Montpellier, France; 3 Laboratoire de Biologie Cellulaire du Développement, EA 3446, Proliférateurs de Péroxysomes, Université Henri Poincaré-Nancy I, Faculté des Sciences, Vandoeuvre-lès-Nancy, France; and 4 CERTO, Faculté Necker-Enfants Malades, Paris, France

Requests for reprints: Gérard Cabello, UMR 866, Différenciation Cellulaire et Croissance (INRA-UMII-ENSAM), Unité d'Endocrinologie Cellulaire, Institut National de la Recherche Agronomique, 2 place Viala, 34060 Montpellier, France. Phone: 33-4-99-61-22-19; Fax: 33-4-67-54-56-94; E-mail: cabello{at}ensam.inra.fr.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Mitochondrial dysfunctions are frequently reported in cancer cells, but their direct involvement in tumorigenesis remains unclear. To understand this relation, we stimulated mitochondrial activity by overexpression of the mitochondrial triiodothyronine receptor (p43) in human dermal fibroblasts. In all clones, this stimulation induced morphologic changes and cell fusion in myotube-like structures associated with the expression of several muscle-specific genes (Myf5, desmin, connectin, myosin, AchR{alpha}). In addition, these clones displayed all the in vivo and in vitro features of cell transformation. This phenotype was related to an increase in c-Jun and c-Fos expression and extinction of tumor suppressor gene expression (p53, p21WAF1, Rb3). Lastly, reactive oxygen species (ROS) production was increased in positive correlation to the stimulation of mitochondrial activity. The direct involvement of mitochondrial activity in this cell behavior was studied by adding chloramphenicol, an inhibitor of mitochondrial protein synthesis, to the culture medium. This inhibition resulted in partial restoration of the normal phenotype, with the loss of the ability to fuse, a strong decrease in muscle-specific gene expression, and potent inhibition of the transformed phenotype. However, expression of tumor suppressor genes was not restored. Similar results were obtained by using N-acetylcysteine, an inhibitor of ROS production. These data indicate that stimulation of mitochondrial activity in human dermal fibroblasts induces cell transformation through events involving ROS production.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Besides their involvement in fuel metabolism, the importance of mitochondria in cell physiology has been extended to the regulation of cell proliferation, differentiation, and apoptosis, all these being processes strongly impaired during the development of oncogenesis. Indeed, inhibition of mitochondrial gene expression induces a potent decrease in cell proliferation (1, 2). In addition, studies done in erythroleukemia, neurons, or myoblasts established that impairment of organelle activity also inhibits cell differentiation (3–5). Our own studies provided evidence that the latter influence resulted from actual regulation of differentiation by mitochondrial activity through the control of myogenin expression (5). Lastly, it is now well established that release of cell death–inducing factors by the organelle is a key event in the induction of cell apoptosis (6) and that disruption or resistance of the apoptotic pathway is an evident "hallmark of cancer" (7).

Many reports have also pointed out the occurrence of mitochondrial dysfunctions in several pathologies, including diabetes (8), degenerative diseases such as myopathies (9), and Parkinson's or Alzheimer's diseases (10, 11). Similarly, alterations of organelle activity have been consistently reported in tumoral tissues (12) and mitochondrial genome mutations have been observed during oncogenic processes (13). Although the significance of these associations between mitochondria and cancer are not really understood, several data clearly suggest that organelle dysfunction could be involved in the induction or development and maintenance of events leading to oncogenic processes. In particular, cybrids obtained by fusion between the cytoplasm of transformed cells and the nucleus of normal cells display the same oncogenic properties as initial cancer cells, thus suggesting that cytoplasmic factors are sufficient to induce tumorigenic events (14, 15).

Among the cytoplasmic factors, the possible involvement of mitochondria is well supported by various studies indicating that experimental inhibition of organelle protein synthesis or depletion of mitochondrial DNA strongly decreases in vitro or in vivo oncogenic phenotype (16, 17). In addition, mitochondria are the major site of free radical production in the cell and this production is frequently altered in tumor tissues (18, 19). Although elevated concentrations of reactive oxygen species (ROS) can induce apoptosis (20), these observations have led to the use of antioxidant molecules in cancer cell therapy (21).

The major influence of triiodothyronine (T3) on mitochondrial activity has been partly explained by the discovery of p43, a mitochondrial T3 receptor (22). This receptor is synthesized through the use of an internal AUG occurring in the c-erbA{alpha}1 transcript, also encoding a T3 nuclear receptor (23). This truncated (43 kDa) form of the thyroid hormone receptor c-ErbA{alpha}1 (TR{alpha}) is located in the mitochondrial matrix (22) and acts as a T3-dependent transcription factor of the mitochondrial genome (24). Besides the importance of this pathway for cell physiology, these findings lead to the possibility that organelle activity can be directly stimulated by p43 overexpression.

In this study, we used this opportunity to study the influence of stimulated mitochondrial activity induced by p43 overexpression in human dermal fibroblasts. We report that such stimulation leads to cell transformation, owing to down-regulation of the expression of tumor-suppressor genes and up-regulation of c-Jun and c-Fos expression, and acquisition of a defective myogenic phenotype linked to the induction of Myf5 expression, a myogenic factor involved in muscle cell specification. In addition, these events are associated with ROS overproduction and are partially overcame by chloramphenicol, an inhibitor of mitochondrial protein synthesis.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell culture and treatment conditions. Primary human dermal fibroblasts from two young female normal controls were used in these experiments. They were independently grown in DMEM supplemented with gentamicin (100 IU/mL) and FCS (10%) at 37°C and 5% CO2.

The pattern of cell fusion was assessed before and after lowering the medium serum concentration at cell confluence (0.5%), a classic procedure used to induce differentiation in myoblasts.

For proliferation assays, cells were plated in 60 mm dishes in triplicate at a density of 5 x 104 cells per dish. They were grown in medium containing FCS at 10% and counted daily over a 5-day period.

To inhibit mitochondrial protein synthesis when needed, chloramphenicol (100 µg/mL) was added to the culture medium and cells were cultured during three passages in the presence of the drug. To assess the involvement of ROS production in this observed phenotype, transformed cells were treated with the antioxidant N-acetylcysteine (NAC, 0.25, 0.5, and 1 mmol/L; Sigma, St. Louis, MO).

Stable transfection. Human fibroblasts constitutively expressing c-erbA{alpha}1 were obtained by stable transfection of the pIRV FE6 expression vector (22). Control fibroblasts were obtained by stable transfection of the pIRV "empty" vector. Ten micrograms of each plasmid carrying G418 resistance were transfected using the calcium phosphate procedure 24 hours after plating. The medium was changed 24 hours later after PBS washes, and amplification was done after 10 days in the presence of G418.

Growth in soft agar and tumorigenicity in nude mice. A double-layer culture technique was used for the study of growth in soft agar. Cells (5 x 104 cells per 60 mm dish) were seeded in 3 mL medium containing 0.3% agar (Diagnostics Pasteur, Marnes- la-Coquette, France) and placed over a bottom agar consisting of 4 mL medium containing 0.6% agar. Cells were fed weekly with 1 mL medium. Two weeks after seeding, colonies were scored.

For analysis of tumorigenic potentialities in vivo, cells were dispersed with trypsin, washed thrice with PBS to remove serum, and resuspended at 1 x 107 cells/mL in a medium without serum. About 2 x 106 cells were injected s.c. into 7-week-old athymic mice. Tumor occurrence and size was monitored weekly for up to 3 months.

Cytoimmunofluorescence and immunohistochemical studies. P43 mitochondrial localization and expression of muscle-specific markers [myosin heavy chain (MHC) and desmin] were assessed by cytoimmunofluorescence. After methanol fixation and appropriate washings, cells were stained with a rabbit polyclonal antibody raised against c-ErbA (RHTII; ref. 22), a mouse anti-human mitochondria monoclonal antibody (MAB1273, Chemicon International, Temecula, CA), a mouse anti-MHC monoclonal antibody [1F11, given by Dr. F. Pons (Institut National de la Sante et de la Recherche Medicale, Montpellier, France)], or a mouse antidesmin monoclonal antibody (D-8281, Sigma) and then incubated with a fluorescein-conjugated antibody raised against mouse or rabbit immunoglobulins. Nuclei were stained with Hoechst 33258 (1 µg/mL).

The fusion index (percentage of nuclei incorporated into myotubes relative to the total number) was calculated to assess the frequency of fusion events.

Immunohistochemical studies were done to detect myosin and desmin expression on tumor paraffin section (using antibodies raised against desmin or myosin from DAKO, Trappes, France) as previously described.

Measurement of cytochrome oxidase activity. Cells plated in coated dishes were harvested in 1 mL PBS and then centrifuged for 5 minutes at 12,000 x g. For enzymatic activity determination, the pellet was resuspended in 50 to 150 µL lysis buffer [10 mmol/L Tris (pH 7.8)] and lysed by three cycles of freezing/defreezing. Total proteins were measured on an aliquot using the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). Cytochrome oxidase was measured as specific activity (5) and was expressed relative to control levels.

Protein level analysis. Protein levels were monitored by Western blotting; 50 µg total proteins were resolved on 10% SDS-PAGE minigels, transferred to polyvinylidene difluoride membranes, and immunodetected using a chemiluminescence kit (Amersham Biosciences, Buckinghamshire, United Kingdom). The following antibodies were used: anti-c-ErbA (RHTII; diluted at 1/1,000; described in ref. 22), MHC (1F11, diluted at 1/500, given by Dr. F. Pons), desmin (D-8281, diluted at 1/1,000; Sigma), p21WAF1 (diluted at 1/1,500; Santa Cruz Biotechnology, Santa Cruz, CA), Rb (clone G2345, diluted at 1/200; PharMingen Biosciences, Erembodegem, Belgium), and p53 (HR 231, diluted at 1/5,000; ref. 25).

In vitro synthesized proteins were used as positive controls for p43 and c-ErbA{alpha}1 (p47) size. These proteins were synthesized by using the rabbit reticulocyte lysate transcription-translation TNT kit (Promega France, Charbonnieres, France) according to the manufacturer's instructions.

RNA level analysis. RNA levels were monitored by Northern blots. Total RNAs (30 µg) were isolated after 48 hours (proliferation), 96 hours (cell confluence), and 168 hours (low serum concentration: cellular fusion) of culture, as described by Chomczynski and Sacchi (26). Membranes were hybridized with labeled cDNA probes using the Megaprime DNA labeling system (Amersham Biosciences). Quantitation was done using a STORM phosphorimager (Molecular Dynamics, Sunnyvale, CA) and normalized relative to 18S.

Cell cycle analysis. Cells were trypsinized and centrifuged for 5 minutes at 400 x g and 4°C. Cell pellets were dried on ice and resuspended in 900 µL of solution containing 25 µg/mL propidium iodide, 0.1% tri-natriumcitrate dihydrate, 10% A-RNase (1 mg/mL in 0.5 mol/L EDTA, PBS), and 0.1% Triton X-100. Analysis of cellular DNA content was determined by collecting 20,000 events using a FACSCalibur flow cytometer and CELLQuest software.

Measurement of reactive oxygen species production. We used two different fluorogenic probes for measuring mitochondrial ROS production, dihydrorhodamine 123 (27), and 2',7'-dichlorofluorescein-diacetate (DCFH-DA) converted to its fluorescent product (DCFH) in cell cytosol by intracellular radicals. Cells were loaded with 1 mL of a PBS solution containing either 150 µmol/L of dihydrorhodamine 123 (Molecular Probes) from a 15 mmol/L stock solution in dimethylformamide or 20 µmol/L DCFH-DA (Molecular Probes) from a 1 mmol/L stock solution in dimethylformamide. Then, cells were replaced at 37°C for 5 or 20 minutes with dihydrorhodamine 123 or DCFH-DA, respectively. After washing, cells were trypsinized and harvested for flow cytometry analysis. In each case, intracellular green fluorescence was measured with excitation at 488 nm and emission at 525 nm (28), by analyzing at least 20,000 living cells per assay.

Statistical analysis. Statistical analyses were done using Student's t test (*P < 0.05; **P < 0.01; ***P < 0.001).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
P43 overexpression in human dermal fibroblasts stimulates mitochondrial activity and induces morphologic changes. After stable independent transfections of the c-erbA{alpha}1 expression vector and selection, 11 clones belonging from the two donors were obtained. As they displayed a similar phenotype, two of them were used for the complete study (MT1 and MT2). They were characterized by an increase in the level of p43, a truncated form of the T3 nuclear receptor acting as a T3 mitochondrial receptor, associated to a clear decrease in the level of the nuclear receptor (Fig. 1A). Cytoimmunofluorescence studies confirmed that overexpressed p43 was specifically addressed to mitochondria (Fig. 1B).



View larger version (40K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Overexpression of p43 in human dermal fibroblasts. A, Western blot of total protein extracts from confluent pIRV (control) or pIRV c-erbA{alpha}1 (MT1 and MT2) stably transfected cells. c-ErbA{alpha}1 (or p47) and p43 in vitro synthesized proteins were used as control. B, cytoimmunofluorescence experiment indicating colocalization of mitochondria and p43 (x630) in control cells and p43-overexpressing cells. C, cytochrome oxidase–specific activity measured in control, MT1, and MT2 cells. Data are expressed as percentage of control cells. Columns, mean of six independent experiments; bars, SE. D, ROS levels measured in control, MT1, and MT2 cells by flow cytometry analysis of dihydrorhodamine oxidation. Data are expressed as percentage of control cells. Columns, mean of five independent experiments; bars, SE. E, ROS levels measured in control, MT1, and MT2 cells by flow cytometry analysis of DCFH-DA. Columns, mean of three independent experiments; bars, SE. Statistically significant differences relative to control cells: *P < 0.05 and **P < 0.01 (Student's t test).

 
As previously shown in other cell types (5, 22), cytochrome oxidase activity was stimulated in the two selected clones (MT1: x5; MT2: x15, relative to control cells, P < 0.05 and P < 0.01, respectively; Fig. 1C). Moreover, in the two clones, we found a significant increase in ROS production (Fig. 1D and E).

In addition to these mitochondrial alterations, we observed important morphologic changes in p43-overexpressing cells. Whereas normal cells and cells transfected with the empty vector displayed a typical dermal fibroblast morphology, cells expressing p43 acquired a compact morphology, with a reduction in the cytoplasmic area (Fig. 2A). In addition, they spontaneously fused in plurinucleated structures looking like myotubes for the MT1 clone or myoballs for the MT2 clone. Fusion processes were strongly enhanced after decreasing serum concentration in the culture medium, a procedure classically used to induce myoblast differentiation (Fig. 2B). However, the striated structure observed in myotubes was not apparent.



View larger version (69K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. Morphologic changes of p43 overexpressing cells. A, phase contrast microscopy shows the occurrence of morphologic changes in human dermal fibroblasts expressing p43 (MT1 and MT2) compared with control fibroblasts in medium containing 10% (top) or 0.5% (bottom) FCS (x100). Cell confluence. B, fusion index calculated during proliferation (P) and under low serum concentration (LS) in control, MT1, and MT2 cells. Columns, mean of four independent experiments; bars, SE. Cytoimmunofluorescence experiment indicating specific MHC (C) and desmin expression (E) in MT1 and MT2 cells. At confluence, cells were cultured using a low serum concentration medium (0.5%). Observations were done 3 days later (x100 and x400 for myosin and x200 for desmin). Data are representative of five (myosin) and three (desmin) independent experiments. D and F, frequency of myosin- and desmin-positive cells measured during proliferation and under low serum concentration in control, MT1, and MT2 cells. Columns, mean of four independent experiments; bars, SE. G, Western blot analysis of MHC and desmin expression in control, MT1, and MT2 cells at the indicated culture stages [P, cell confluence (C), and LS]. Data are representative of three independent experiments. H, Northern blot analysis of AchR{alpha} and Myf5 mRNA expression in control, MT1, and MT2 cells at the indicated culture stages (P, C, and LS). The membrane was reprobed using 18S as a loading control. Data are representative of three independent experiments. Statistically significant differences relative to control cells: **P < 0.01 and ***P < 0.001 (Student's t test).

 
As we observed fusion events in MT1 and MT2 cells, we checked for the possible expression of genes encoding muscle-specific proteins. Cytoimmunofluorescence studies indicated that, as expected, control cells did not express myosin or desmin. However, MT1 and MT2 cells expressed these two muscle-specific proteins (Fig. 2C-F), but not T-troponin (another muscle-specific protein; data not shown). Western blotting experiments confirmed that MHC and desmin expression was restricted to p43-overexpressing cells (Fig. 2G). In addition, the frequency of cells expressing these proteins increased in relation to the increase in the value of the fusion index (Fig. 2D and F). In contrast to other myogenic factors, Myf 5 transcripts were easily detected in MT1 and MT2 clones (Fig. 2H) but not in control cells [data not shown from reverse transcription-PCR (RT-PCR); Fig. 2H]. In addition, only p43-overexpressing cells expressed AChR{alpha} (subunit {alpha} of acetylcholine receptor) mRNA, a specific marker of muscle cells (Fig. 2H). Taken together, these data clearly indicate that p43 overexpression in human dermal fibroblasts induces a myogenic phenotype characterized by cell fusion and expression of genes encoding muscle-specific proteins. However, our data point out the acquisition of a defective phenotype with absence of MyoD, myogenin, and T-troponin expression and the lack of a striated structure.

P43 overexpression in human dermal fibroblasts induces cell transformation. In addition to these morphologic changes, we first observed that, in contrast to control cells, MT1 and MT2 clones formed multilayers of cells (Fig. 3A), thus suggesting a loss of contact inhibition. In addition, MT1 and MT2 cells displayed a large increase in their proliferation rate relative to control cells (Fig. 3B) as their number was five times greater than in control cells after 4 days of culture. To test the possible induction of cell transformation by p43 overexpression, we next studied anchorage-independent growth potential, another well-established property of transformed cells. When plated in semisolid medium, the control cells remained in suspension as single cells and never formed colonies, whereas the MT1 (P < 0.05) and MT2 (P < 0.01) clones grew in large colonies (Fig. 3C). The number and size of these colonies were greater in MT2 cells characterized by higher mitochondrial activity than in MT1 cells. Furthermore, MT1 and MT2 cells displayed a lower requirement for serum growth factors. Their proliferation rate was maintained in media with 0.5% FCS in contrast to control cells that became quiescent as indicated by an exclusive accumulation in the G0-G1 phase (Fig. 3D).



View larger version (59K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Overexpression of p43 promotes tumorigenic events in vitro. A, phase contrast microscopy (x100) shows the potentiality of p43-expressing cells to form foci in culture. Cells were grown in medium containing 10% (v/v) FCS for 5 days after confluence. B, effects of p43 overexpression on cell proliferation in medium containing 10% (v/v) FCS. Cell numbers were determined daily. Points, mean of four independent experiments; bars, SE. C, phase contrast microscopy (x100) of control or p43-expressing cells grown in soft agar medium (left). Quantitation of colonies growing in each dish of soft agar medium from 1 x 105 control, MT1, and MT2 cells (right). Columns, mean of three independent experiments; bars, SE; ND, none detected. D, cell cycle profile of control, MT1, and MT2 cells growing in medium containing 0.5% serum. Cells were fixed and stained with propidium iodide (PI) and then analyzed by flow cytometric analysis. The percentage of cells in each stage of the cell cycle (G1, S, and G2-M) is indicated. Statistically significant differences relative to control cells: *P < 0.05 and **P < 0.01 (Student's t test).

 
Lastly, as a final examination of p43 transforming potential, we tested the ability of MT2 cells to promote tumor formation in athymic nude mice. After cell injection in the right flank, three of five mice injected with MT2 cells and two of five with MT1 cells displayed large tumors (Fig. 4A). By contrast, none of the mice injected with control cells developed detectable tumors. Analysis of these tumors revealed significant myosin and desmin expression and the occurrence of few plurinucleated structures (Fig. 4B). However, when cultured, tumor cells displayed exactly all the features of MT2 or MT1 clones including extensive cell fusion (data not shown).



View larger version (75K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Overexpression of p43 promotes tumorigenic events in vivo. A, tumor formation in athymic nude mice following s.c. injection with control or p43-overexpressing cells (left) and growth curves of tumors in individual animals (right). B, immunohistochemical studies of myosin and desmin expression in tumor section (x200, left and x400, right).

 
These results indicate that stimulation of mitochondrial activity by increasing amounts of p43 is able to promote all in vivo and in vitro properties of cell transformation. These findings clearly highlight the oncogenic potency of p43, a mitochondrial transcription factor synthesized from the proto-oncogene c-erbA{alpha}1 transcript.

P43 overexpression induces changes in gene expression leading to the transformed phenotype. As cell transformation is associated to decreased expression or to a loss of tumor suppressor functionality and/or to proto-oncogene activation, we studied p53, p21WAF1, Rb (tumor suppressor genes), c-Jun, and c-Fos expression. P53, p21WAF1, and Rb transcripts were easily detected by Northern blot and by RT-PCR (data not shown) in control cells, but not in MT1 and MT2 clones (Fig. 5A). Western blot analyses confirmed the absence of p53, Rb, and p21WAF1 proteins in these cells (Fig. 5B). In addition, we found that c-Jun and c-Fos protein levels were up-regulated by p43 overexpression (Fig. 5C). Altogether, these data provide evidence of the extinction of three tumor suppressor genes and the induction of expression of two proto-oncogenes in p43-overexpressing cells, thus explaining cell transformation.



View larger version (64K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. P43 overexpression abrogates tumor suppressor gene expressions. Northern blot (A) and Western blot (B) analyses of three tumor suppressor gene expressions (Rb, p21WAF1, and p53) in control (pIRV) or MT1 and MT2 (p43-overexpressing) cells at the indicated times (P, C, and LS). 18S is used as a loading control. Data are representative of three independent experiments. C, Western blot analysis of two cellular oncogenes, c-Fos and c-Jun, in control, MT1, and MT2 cells at confluence. Data are representative of three independent experiments.

 
Inhibition of mitochondrial protein synthesis or reactive oxygen species production partially restores a normal cell phenotype. To assess the role of the increase in mitochondrial activity induced by p43 overexpression in the initiation of the myogenic and transformed phenotypes of dermal fibroblasts, we used chloramphenicol, an inhibitor of mitochondrial protein synthesis, to inhibit the organelle activity of MT1 and MT2 clones.

As expected, chloramphenicol strongly inhibited mitochondrial activity assessed by measurement of cytochrome oxidase activity (Fig. 6A). As shown in Fig. 6B and C, this treatment effectively abolished the ability of MT1 and MT2 cells to fuse in plurinucleated structures, but did not restore the normal fibroblastic morphology. This influence was associated with a strong decrease in the expression of genes encoding muscle-specific proteins, Myf5 and AchR{alpha}, assessed by Northern blot (Fig. 6D) and MHC by Western blot (Fig. 6E).



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. Decrease of mitochondrial activity down-regulates the partial myogenic phenotype obtained after p43 overexpression. A, cytochrome oxidase–specific activity measured at cell confluence in p43-overexpressing cells (MT1 and MT2) treated or not with chloramphenicol (chl; 100 µg/mL). Columns, mean of six independent experiments; bars, SE. B, cytoimmunofluorescence experiment using an antibody raised against MHC. At confluence, cells treated or not with chloramphenicol were cultivated under low serum concentration medium (0.5%) and analyses were done 3 days later (x100). C, fusion index values 3 days after decreasing serum in MT1, MT1 + chl, MT2, and MT2 + chl cells. Columns, mean of three independent experiments; bars, SE. D, Northern blot analysis of AchR{alpha} and Myf5 mRNAs at the indicated times (P, C, and LS). Results were normalized to 18S level. Data are representative of three independent experiments. E, Western blot analysis of MHC protein expression at the indicated times (P, C, and LS). Data representative of three independent experiments. Statistically significant differences: *P < 0.05; **P < 0.01; ***P < 0.001 (Student's t test).

 
Similarly, chloramphenicol strongly reduced the proliferation rate of MT1 and MT2 cells (day 5 of culture: 20-fold reduction in the number of cells; Fig. 7A), moderately reduced the proliferation rate of control cells (day 5: 2-fold reduction) as well as their ability to grow in semisolid agar (Fig. 7B) or in low serum medium (Fig. 7C), and restored contact inhibition, as reflected by the absence of multilayer growth in culture (data not shown). However, this treatment did not restore the expression of the three tumor suppressor genes and did not inhibit the expression of the two oncogenes (data not shown).



View larger version (48K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 7. Inhibition of mitochondrial activity partially reverses cellular transformation induced by p43 overexpression. A, effects of chloramphenicol on control, MT1, and MT2 cell proliferation in medium containing 10% serum; cell numbers were determined daily. Points, mean of three independent experiments; bars, SE. B, phase contrast microscopy (x100) observation of chloramphenicol influence on growth in soft agar medium (left). Quantitation of colonies growing in each dish of soft agar medium from 1 x 105 MT1, MT1 + chl, MT2, and MT2 + chl cells (right). Statistically significant differences: **P < 0.01; ***P < 0.001 (Student's t test). C, cell cycle profile of MT1 and MT2 cells treated or not with chloramphenicol and growing in medium containing 0.5% serum. The percentage of cells in each stage of the cell cycle (G1, S, and G2-M) is indicated.

 
As chloramphenicol significantly reduced ROS production (Fig. 8A), to assess the involvement of these molecules in MT1 and MT2 phenotypes we studied the influence of NAC, an antioxidant molecule. We found that NAC treatment mimicked the chloramphenicol effect by strongly reducing MT1 and MT2 proliferation rate (Fig. 8B) and ability to grow in soft agar (Fig. 8C).



View larger version (50K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 8. The antioxidant NAC partially reverses cellular transformation induced by p43 overexpression. A, effect of chloramphenicol on ROS levels in MT1 and MT2 cells (flow cytometry analysis of DCFH-DA). Columns, mean of three independent experiments; bars, SE. B, influence of NAC on MT1 and MT2 cell proliferation in medium containing 10% serum; cell numbers were determined daily. Several NAC concentrations were used (0.25, 0.5, and 1 mmol/L). Points, mean of three independent experiments; bars, SE. C, phase contrast microscopy (x100) observation of NAC influence on growth in soft agar medium. Quantitation of colonies growing in each dish of soft agar medium from 1 x 105 cells in MT1, MT1 + 0.25 mmol/L, MT1 + 0.5 mmol/L, MT1 + 1 mmol/L and MT2, MT2 + 0.25 mmol/L, MT2 + 0.5 mmol/L NAC, MT2 + 1 mmol/L. Columns, mean of three independent experiments; bars, SE. Statistically significant differences from control cells: *P < 0.05; **P < 0.01; ***P < 0.001 (Student's t test).

 
Finally, these results suggest that the stimulation of mitochondrial activity by p43 overexpression is directly involved, through an increase in ROS production, in the acquisition of the defective myogenic phenotype, and induced cell transformation. However, as inhibition of mitochondrial activity did not completely reverse transformation-associated events (extinction of tumor suppressor genes and oncogene overexpression) some features seem to be irreversible, as also shown by the persistence of morphologic changes.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this study, we provide data establishing the induction of cell transformation by stimulation of mitochondrial activity through p43 overexpression: (a) stimulation of mitochondrial activity is associated to human dermal fibroblast transformation in association with the acquisition of a defective myogenic phenotype; (b) inhibition of organelle activity partially reverses the transformed defective myogenic phenotype.

P43 overexpression stimulates mitochondrial activity. C-erbA{alpha}1 simultaneously encodes a nuclear and a mitochondrial T3 receptor, synthesized through the use of an internal AUG occurring in the TR{alpha} transcript (29). Consequently, TR{alpha} transfection might result theoretically in a simultaneous increase in nuclear and mitochondrial T3 receptor levels. In fact, we found a decrease in the nuclear receptor protein level. This point is under investigation, but one possibility is that a stimulation of mitochondrial activity could reduce stability of the nuclear receptor; alternatively, it could affect the expression, translation, or degradation of a putative RNA-binding protein involved in the selection of the first or second AUG leading to nuclear or mitochondrial receptor synthesis. In addition, we found that c-ErbA{alpha}1 overexpression results in a sharp increase in p43 levels in human dermal fibroblasts, a result not observed with the same intensity in myoblasts or preadipocytes (data not shown). However, we have already reported that despite the occurrence of nearly similar levels of TR{alpha} transcripts in the two tissues, p43 protein levels are very important in brown adipose tissue, whereas they are not detected in adult brain (22, 30). Similarly, whereas TR{alpha} expression is lower in liver (31), p43 levels are particularly abundant (22, 30). All these data point to the occurrence of a cell-specific regulation in the use of the internal AUG giving rise to p43.

After having established that the overexpressed p43 protein was correctly addressed into mitochondria, we observed the induction of potently stimulated mitochondrial activity reflected by a 5-fold (MT1) or 15-fold (MT2) increase in cytochrome oxidase activity associated with more moderate stimulation of other parameters reflecting organelle activity (oxygen consumption), in agreement with previous studies (5, 22). In parallel, p43 also increased ROS production, in good correlation with the increase in cytochrome oxidase activity found in MT1 and MT2 clones.

P43 overexpression induces a defective myogenic phenotype in human dermal fibroblasts. Unexpectedly, we found that p43 overexpression induced morphologic changes and especially the ability of cells to fuse in syncytial structures, a phenomenon potentiated by decreasing serum concentration in the culture medium, as currently used to induce myoblast differentiation. These morphologic changes were associated with the expression of muscle-specific genes, such as desmin, connectin (data not shown), AchR{alpha}, and MHC. All these changes could be related to the induction of Myf5 expression, a myogenic factor involved primarily in the induction of the myogenic phenotype (32). However, neither MyoD nor myogenin transcripts were detected in these cells, explaining the acquisition of a defective myogenic phenotype characterized by the absence of several muscle-specific proteins, such as T-troponin, and other structural proteins that can explain the lack of the striated structure typical of skeletal muscle.

In agreement with these data indicating that Myf5 expression alone is sufficient to induce a myogenic phenotype, Rudnicki et al. (33) have previously reported that MyoD is not essential for skeletal muscle development in mice, revealing some degree of functional redundancy in the control of the skeletal myogenic developmental program. Indeed, inactivation of MyoD in mice led to an increase in Myf5 mRNA level and to normal or subnormal muscle development in these mice. Furthermore, constitutive expression of one of the four myogenic factors is sufficient to induce a myogenic program in nonmuscle cells (34). In addition, although our histologic analysis only detected the occurrence of few syncytial structures in tumors induced by cell injections in nude mice, cultured cells from these tumors recovered a full ability to fuse. These data are in agreement with previous reports indicating that, whereas muscle fibers are absent in myogenin–/– mice, cultured myoblasts derived from these animals are able to fuse in myotubes (35).

P43 overexpression induces human dermal fibroblast transformation. Besides the induction of a myogenic phenotype, the strong increase in mitochondrial activity resulting from p43 overexpression induces the well-established hallmarks of cellular transformation (7). Overexpressing p43 cells lost contact-mediated growth inhibition, exhibited reduced serum growth requirements, and were fully protected from apoptosis following growth factor deprivation. Furthermore, we found that, unlike control cells, p43-expressing cells formed colonies in semisolid medium and tumors when injected into athymic nude mice. In combination with the simultaneous observation of a defective myogenic phenotype, these data clearly suggest that p43 overexpression induces a rhabdomyosarcoma-like phenotype. Indeed, rhabdomyosarcoma, the most common soft-tissue sarcoma of childhood, is characterized by expression of skeletal muscle markers and alterations of oncosuppressor genes. However, the origin of rhabdomyosarcoma remains unclear (36).

Study of changes in the expression of some genes involved in the induction or prevention of cell transformation revealed some interesting data. First, we found that p43 overexpression stimulates expression of c-Jun and c-Fos, two important members of activator protein 1 (AP-1) complexes. The proto-oncogene c-jun, encoding a major component of the transcription factor AP-1, is known to fulfill important functions in cell proliferation, differentiation (37, 38), and transformation (39). Several studies have established the transformation potentialities of AP-1 complexes via c-Jun expression in rat embryo cells (40) and the c-Fos requirement for malignant progression in skin tumors (41). Furthermore, inhibition of AP-1 activity reversed cell transformation in JB6 mouse epidermal cells (42). In addition, c-Jun has been shown to be involved in the induction of Myf5 by several regulators (dexamethasone and anisomycin; ref. 43). Consequently, the increase in c-Jun expression in MT1 and MT2 clones could partly mediate the induction of Myf5 and the acquisition of a defective myogenic phenotype.

Besides the stimulated expression of these cellular oncogenes, we also found that p43 overexpression fully abrogated the expression of three tumor suppressor genes, p53, Rb, and p21WAF1. As the activation of cellular oncogenes and/or the loss of function of tumor suppressors are involved in oncogenic processes, all these data satisfactorily explain the induction of transformation processes by p43 overexpression. Interestingly, these three tumor suppressor genes seem to be involved in rhabdomyosarcoma. For instance, a simultaneous inactivation of both p53 and Rb in mice induces rhabdomyosarcoma development (44). In addition, according to Aurade et al. (43), p21WAF1 is methylated and hypoexpressed in rhabdomyosarcoma (45). All these data well support the possibility that, by inducing a dramatic decrease in p53, Rb, and p21WAF1 expression, a potent stimulation of mitochondrial activity through p43 expression in dermal fibroblasts could induce a rhabdomyosarcoma-like phenotype.

Furthermore, the repression of c-Fos expression by Rb (46) suggests the existence of a functional link between the extinction of tumor suppressor gene expression and the stimulation of c-Fos expression. These results thus established the oncogenic potentiality of the mitochondrial transcription factor, p43. Since its characterization, the c-erbA{alpha}1 gene has been considered as a proto-oncogene due to the occurrence of a mutated version in the avian erythroblastosis virus (47, 48); however, there has been no direct experimental proof of its oncogenic properties. In this study, we showed for the first time that c-erbA{alpha}1 overexpression alone is sufficient to induce dermal fibroblast transformation and that, unexpectedly, this influence is mediated by the product of this gene addressed into mitochondria.

Stimulation of mitochondrial activity is directly involved in the acquisition of the defective myogenic phenotype and in the induction of cell transformation. As previously shown, p43 overexpression induced a potent stimulation of mitochondrial activity characterized by stimulation of cytochrome oxidase activity. To find out if this event was directly involved in the cell phenotype changes observed in this study, we used chloramphenicol, an inhibitor of mitochondrial protein synthesis. As expected, chloramphenicol strongly inhibited mitochondrial activity. This influence was associated with strong inhibition of the myogenic phenotype characterized by almost complete abrogation of cell fusion, and potent inhibition of the expression of genes specifically expressed in muscle tissue, probably due to the decrease in Myf5 expression.

In addition, we also found that inhibition of mitochondrial activity by chloramphenicol was associated with a partial reversion of the transformed phenotype. Not only did cell proliferation decrease, but cells did not grow in foci and lost their ability to proliferate in low serum medium. Moreover, their ability to grow in semisolid agar decreased, but expression of tumor suppressor genes or oncogenes was not affected (data not shown).

Altogether, these results show that stimulation of mitochondrial activity is directly involved in the changes occurring in the dermal fibroblast phenotype, but that some genetic programs are probably not reversible after their induction.

ROS production has frequently been implicated in the initiation and promotion phases of tumorigenesis (49). The electron transport chain of mitochondria is considered as a major source of ROS. In this study, stimulation of mitochondrial activity is associated with an increase in ROS cellular levels. In turn, several reports have shown that ROS production affects nuclear gene expression by altering the activity of some transcriptional factors (50, 51). In particular, nuclear factor {kappa}B and AP-1 have been identified as regulated by the intracellular redox state. In agreement with our data, c-Fos and c-Jun are induced by relatively small amounts of hydrogen peroxide, superoxide, nitric oxide, and other inducers of oxidative stress (52). In addition, the involvement of ROS production is also well supported by the observation that phenotypic reversion induced by chloramphenicol is associated with a significant reduction in ROS levels (data not shown).

In this study, we report that c-erbA{alpha}1 overexpression, through increased amounts of the mitochondrial T3 receptor p43, induces phenotypic changes in human dermal fibroblasts characterized by the acquisition of defective myogenic features and cell transformation, with a resemblance to rhabdomyosarcoma cells. This work constitutes the first experimental induction of a rhabdomyosarcoma-like phenotype. In addition, we have provided evidence suggesting that p43-induced stimulation of mitochondrial activity is directly involved in these events, probably through ROS production. Overall, we have brought new insights into the possible involvement of mitochondria in oncogenic processes, and we have established that the c-erbA{alpha} gene must indeed be considered as a proto-oncogene.


   Acknowledgments
 
Grant support: Ligue Départementale Contre le Cancer (Hérault) and Association française contre les myopathies.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/12/04. Revised 2/ 8/05. Accepted 3/ 7/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Van Den Bogert C, Spelbrink JN, Dekker HL. Relationship between culture conditions and the dependency on mitochondrial function of mammalian cell proliferation. J Cell Physiol 1992;152:632–8.[CrossRef][Medline]
  2. Lou J, Anderson SL, Xing L, Rubin BY. Suppression of mitochondrial mRNA levels and mitochondrial function in cells responding to the anticellular action of interferon. J Interferon Res 1994;14:33–40.[Medline]
  3. Kaneko T, Watanabe T, Oishi M. Effect of mitochondrial protein synthesis inhibitors on erythroid differentiation of mouse erythroleukemia (Friend) cells. Mol Cell Biol 1988;8:3311–5.[Abstract/Free Full Text]
  4. Vayssière JL, Cordeau-Lossouarn L, Larcher JC, Basseville M, Gros F, Croizat B. Participation of the mitochondrial genome in the differentiation of the neuroblastoma cells. In Vitro Cell Dev Biol 1992;28A:763–72.[Medline]
  5. Rochard P, Rodier A, Casas F, et al. Mitochondrial activity is involved in the regulation of myoblast differentiation through myogenin expression and activity of myogenic factors. J Biol Chem 2000;275:2733–44.[Abstract/Free Full Text]
  6. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003;112:481–90.[CrossRef][Medline]
  7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.[CrossRef][Medline]
  8. Hess JF, Parisi MA, Bennet JL, Clayton DA. Impairment of mitochondria transcription termination by a point of mutation associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1991;351:236–9.[CrossRef][Medline]
  9. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999;283:1482–8.[Abstract/Free Full Text]
  10. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994;63:2179–84.[Medline]
  11. Brown GC. Nitric oxide inhibition of cytochrome oxidase and mitochondrial respiration: implications for inflammatory, neurodegenerative and ischaemic pathologies. Mol Cell Biochem 1997;174:189–92.[CrossRef][Medline]
  12. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer 2002;1:9.[CrossRef][Medline]
  13. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998;20:291–3.[CrossRef][Medline]
  14. Jonasson J, Povey S, Harris H. The analysis of malignancy by cell fusion. VII. Cytogenetic analysis of hybrids between malignant and diploid cells and of tumours derived from them. J Cell Sci 1977;24:217–54.[Medline]
  15. Howell AN, Sager R. Tumorigenicity and its suppression in cybrids of mouse and Chinese hamster cell lines. Proc Natl Acad Sci U S A 1978;75:2358–62.[Abstract/Free Full Text]
  16. van den Bogert C, Dontje BH, Holtrop M, et al. Arrest of the proliferation of renal and prostate carcinomas of human origin by inhibition of mitochondrial protein synthesis. Cancer Res 1986;46:3283–9.[Abstract/Free Full Text]
  17. Cavalli LR, Varella-Garcia M, Liang BC. Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ 1997;8:1189–98.[Abstract]
  18. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794–8.[Abstract/Free Full Text]
  19. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002;3:420–5.[CrossRef][Medline]
  20. Slater AF, Nobel CS, Orrenius S. The role of intracellular oxidants in apoptosis. Biochim Biophys Acta 1995;1271:59–62.[Medline]
  21. Gate L, Paul J, Ba GN, Tew KD, Tapiero H. Oxidative stress induced in pathologies: the role of antioxidants. Biomed Pharmacother 1999;53:169–80.[CrossRef][Medline]
  22. Wrutniak C, Cassar-Malek I, Marchal S, et al. A 43-kDa protein related to c-Erb A{alpha}1 is located in the mitochondrial matrix of rat liver. J Biol Chem 1995;270:16347–54.[Abstract/Free Full Text]
  23. Bigler J, Eisenmann RN. C-erb A encodes multiple proteins in chicken erythroid cells. Mol Cell Biol 1988;8:4155–61.[Abstract/Free Full Text]
  24. Casas F, Rochard P, Rodier A, et al. A variant form of the nuclear triiodothyronine receptor c-ErbA{alpha}1 plays a direct role in regulation of mitochondrial RNA synthesis. Mol Cell Biol 1999;19:7913–24.[Abstract/Free Full Text]
  25. Legros Y, Meyer A, Ory K, Soussi T. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene 1994;9:3689–94.[Medline]
  26. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–9.[Medline]
  27. Miles AM, Bohle DS, Glassbrenner PA, Hansert B, Wink DA, Grisham MB. Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J Biol Chem 1996;271:40–7.[Abstract/Free Full Text]
  28. Yamane Y, Furuichi M, Song R, et al. Expression of multidrug resistance protein/GS-X pump and {gamma}-glutamylcysteine synthetase genes is regulated by oxidative stress. J Biol Chem 1998;273:31075–85.[Abstract/Free Full Text]
  29. Bigler J, Hokanson W, Eisenmann RN. Thyroid hormone receptor transcriptional activity is potentially autoregulated by truncated forms of the receptor. Mol Cell Biol 1992;12:2406–17.[Abstract/Free Full Text]
  30. Casas F, Domenjoud L, Rochard P, et al. A 45 kDa protein related to PPAR{gamma}2, induced by peroxisome proliferators, is located in the mitochondrial matrix. FEBS Lett 2000;478:4–8.[CrossRef][Medline]
  31. Schwartz HL, Strait KA, Ling NC, Oppenheimer JH. Quantitation of rat tissue thyroid hormone binding receptor isoforms by immunoprecipitation of nuclear triiodothyronine binding capacity. J Biol Chem 1992;267:11794–9.[Abstract/Free Full Text]
  32. Ott MO, Bober E, Lyons G, Arnold H, Buckingham M. Early expression of the myogenic regulatory gene, myf-5, in precursor cells of skeletal muscle in the mouse embryo. Development 1991;111:1097–107.[Abstract/Free Full Text]
  33. Rudnicki MA, Braun T, Hinuma S, Jaenisch R. Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. Cell 1992;71:383–90.[CrossRef][Medline]
  34. Olson EN, Brennan TJ, Chakraborty T, et al. Molecular control of myogenesis: antagonism between growth and differentiation. Mol Cell Biochem 1991;104:7–13.[Medline]
  35. Nabeshima Y, Hanaoka K, Hayasaka M, Esumi E, Li S, Nonaka I. Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature 1993;364:532–5.[CrossRef][Medline]
  36. Merlino G, Helman LJ. Rhabdomyosarcoma—working out the pathways. Oncogene 1999;18:5340–8.[CrossRef][Medline]
  37. Bengal E, Ransone L, Scharfmann R, et al. Functional antagonism between c-Jun and MyoD proteins: a direct physical association. Cell 1992;68:507–19.[CrossRef][Medline]
  38. Li L, Chambard JC, Karin M, Olson EN. Fos and Jun repress transcriptional activation by myogenin and MyoD: the amino terminus of Jun can mediate repression. Genes Dev 1992;6:676–89.[Abstract/Free Full Text]
  39. Schutte J, Viallet J, Nau M, Segal S, Fedorko J, Minna J. jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun. Cell 1989;59:987–97.[CrossRef][Medline]
  40. Alani R, Brown P, Binetruy B, et al. The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol 1991;11:6286–95.[Abstract/Free Full Text]
  41. Saez E, Rutberg SE, Mueller E, et al. c-Fos is required for malignant progression of skin tumors. Cell 1995;82:721–32.[CrossRef][Medline]
  42. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A 1994;91:609–13.[Abstract/Free Full Text]
  43. Aurade F, Pfarr CM, Lindon C, et al. The glucocorticoid receptor and AP-1 are involved in a positive regulation of the muscle regulatory gene myf5 in cultured myoblasts. J Cell Sci 1997;110:2771–9.[Abstract]
  44. Teitz T, Chang JC, Kitamura M, Yen TS, Kan YW. Rhabdomyosarcoma arising in transgenic mice harboring the ß-globin locus control region fused with simian virus 40 large T antigen gene. Proc Natl Acad Sci U S A 1993;90:2910–4.[Abstract/Free Full Text]
  45. Chen B, He L, Savell VH, Jenkins JJ, Parham DM. Inhibition of the interferon-{gamma}/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res 2000;60:3290–8.[Abstract/Free Full Text]
  46. Robbins PD, Horowitz JM, Mulligan RC. Negative regulation of human c-fos expression by the retinoblastoma gene product. Nature 1990;346:668–71.[CrossRef][Medline]
  47. Sap J, Munoz A, Damm K, et al. The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 1986;324:635–40.[CrossRef][Medline]
  48. Weinberger C, Thompson EB, Ong S, Lebo R, Gruol DJ, Evans R. The c-erb A gene encodes a thyroid hormone receptor. Nature 1986;324:641–6.[CrossRef][Medline]
  49. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996;32A:30–8.
  50. Cimino F, Esposito F, Ammendola R, Russo T. Gene regulation by reactive oxygen species. Curr Top Cell Regul 1997;35:123–48.[Medline]
  51. Hsu TC, Young MR, Cmarik J, Colburn NH. Activator protein 1 (AP-1)- and nuclear factor {kappa}B (NF-{kappa}B)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 2000;28:1338–48.[CrossRef][Medline]
  52. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47–95.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
S. Yang, B. J. Misner, R. J. Chiu, and F. L. Meyskens Jr
Redox effector factor-1, combined with reactive oxygen species, plays an important role in the transformation of JB6 cells
Carcinogenesis, November 1, 2007; 28(11): 2382 - 2390.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grandemange, S.
Right arrow Articles by Wrutniak-Cabello, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grandemange, S.
Right arrow Articles by Wrutniak-Cabello, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online